BridgeBio Oncology Therapeutics, Inc. (BBOT): who owns it and who trades it
As of Nov 16, 2026, no open-market insider purchases or sales of BBOT were reported in the last 12 months. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling BridgeBio Oncology Therapeutics
From the latest filingsOverall: more buying than selling. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns BBOT
67 funds and institutions reported BBOT shares worth $453M at the end of Q2 2026, about 74% of the company. The largest holder is Cormorant Asset Management, LP with 22.3%.
Funds and institutions (13F) 74%Everyone else 26%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Cormorant Asset Management, LP | 17.88M | 22.34% | $136M | No change |
| Deerfield Management Company, L.P. | 4.89M | 6.10% | $37.2M | No change |
| Omega Fund Management, LLC | 3.29M | 4.11% | $25.1M | No change |
| EcoR1 Capital, LLC | 2.82M | 3.53% | $21.5M | No change |
| Alphabet Inc. | 2.82M | 3.53% | $21.5M | No change |
| Wellington Management Group LLP | 2.79M | 3.49% | $21.3M | -1% |
| Enavate Sciences Gp, LLC | 2.63M | 3.28% | $20M | No change |
| Citadel Advisors LLC | 2.62M | 3.27% | $19.9M | +4% |
| Novo Holdings A/s | 2.25M | 2.81% | $17.1M | +3% |
| BlackRock, Inc. | 2.15M | 2.69% | $16.4M | +3% |
| Vanguard Capital Management LLC | 2.01M | 2.51% | $15.3M | +272% |
| Laurion Capital Management LP | 2.00M | 2.50% | $15.3M | +4% |
| Armistice Capital, LLC | 1.76M | 2.20% | $13.4M | +33% |
| State Street Corp | 1.04M | 1.30% | $7.9M | +358% |
| Aisling Capital Management LP | 1.02M | 1.27% | $7.8M | No change |
| Opaleye Management Inc. | 700,000 | 0.87% | $5.3M | +1214% |
| Geode Capital Management, LLC | 622,351 | 0.78% | $4.7M | +7% |
| Granahan Investment Management, LLC | 558,526 | 0.70% | $4.3M | +142% |
| Sphera Funds Management Ltd. | 460,985 | 0.58% | $3.5M | New |
| Adage Capital Partners Gp, L.l.c. | 400,000 | 0.50% | $3M | No change |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
No BBOT insider reported an open-market purchase or sale in the last 12 months.
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
BBOT short interest
Low short interest. 4.3% of BBOT shares are sold short: about 1 share in 23. Over the last 12 reports the number of shares short went up 6%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 3.47M BBOT shares were sold short, 4.3% of the shares outstanding, down 9.8% from the report before. At the average daily volume of 680,248 shares, buying them all back would take about 5.1 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 3.47M | 4.33% | -10% | 680,248 | 5.1 |
| Oct 15, 2026 | 3.85M | 4.80% | +14% | 542,651 | 7.1 |
| Sep 30, 2026 | 3.37M | 4.21% | -6% | 624,657 | 5.4 |
| Sep 15, 2026 | 3.60M | 4.49% | -42% | 824,822 | 4.4 |
| Aug 31, 2026 | 6.19M | 7.73% | +7% | 298,249 | 20.8 |
| Aug 14, 2026 | 5.81M | 7.24% | -0% | 234,207 | 24.8 |
| Jul 31, 2026 | 5.83M | 7.28% | +2% | 280,563 | 20.8 |
| Jul 15, 2026 | 5.69M | 7.11% | +9% | 451,434 | 12.6 |
| Jun 30, 2026 | 5.21M | 6.51% | +32% | 726,372 | 7.2 |
| Jun 15, 2026 | 3.94M | 4.92% | +2% | 251,629 | 15.7 |
| May 29, 2026 | 3.87M | 4.83% | +18% | 464,305 | 8.3 |
| May 15, 2026 | 3.28M | 4.09% | -1% | 323,701 | 10.1 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
BridgeBio Oncology Therapeutics company events
BridgeBio Oncology Therapeutics filed 11 reports on Form 8-K in the last 12 months, 5 of them about an important change (leadership). The latest was on Nov 10, 2026.
- Nov 10, 2026ResultsReleased financial results. Filing
- Nov 5, 2026LeadershipDeparture of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
- Sep 8, 2026AnnouncementBridgeBio Oncology Therapeutics, Inc. issued a press release titled “ BBOT Announces New BBO-8520 Data; Highlights Strategic Focus on 2L+ NSCLC BBO-8520 Combination as Well as BBO-11818 and BBO-10203 Combinations in KRAS-Mutant Cancers .” A copy of the press release is attached as Exhibit 99.1 to… Filing
- Aug 11, 2026ResultsReleased financial results. Filing
- Jun 22, 2026LeadershipDeparture of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
- May 12, 2026ResultsReleased financial results. Filing
- Apr 29, 2026LeadershipDeparture of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
- Apr 23, 2026LeadershipDeparture of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
- Mar 26, 2026LeadershipDeparture of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
- Mar 5, 2026ResultsReleased financial results. Filing
- Jan 7, 2026AnnouncementBridgeBio Oncology Therapeutics, Inc. issued a press release titled “ BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3K α Pipeline Programs .” A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
BridgeBio Oncology Therapeutics financials
Famous investors that hold BBOT
4 of the 50 well-known investors we track reported holding BBOT in their latest 13F filing. The largest position is Ken Griffin's, worth $11.1M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 2.70M | $11.1M | 0.0% | +3% |
| Israel Englander · Millennium Management | Q3 2026 | 144,430 | $592K | 0.0% | +37% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 64,000 | $262K | 0.0% | +9% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 29,570 | $121K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named BBOT in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 13, 2026 | Deerfield Mgmt, L.P. | 13G/A | 2.0% |
| Nov 13, 2026 | Deerfield Mgmt, L.P. | 13G/A | 2.0% |
Questions about BridgeBio Oncology Therapeutics, Inc. (BBOT) stock
Who owns the most BBOT stock?
The largest reported owner of BridgeBio Oncology Therapeutics, Inc. (BBOT) is Cormorant Asset Management, LP, with 22.3% of the company. In total, 67 funds and institutions reported holding BBOT at the end of Q2 2026, together about 74% of the shares. See the largest owners.
Are BBOT insiders buying or selling?
No BBOT insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.
What is the short interest in BBOT?
As of Oct 30, 2026, 3.47M BBOT shares were sold short, 4.3% of the shares outstanding, down 9.8% from the report before. At the average daily volume of 680,248 shares, buying them all back would take about 5.1 trading days (days to cover). See the history.
Which famous investors hold BBOT?
4 of the 50 well-known investors we track reported BBOT in their latest 13F filing, including Ken Griffin, Israel Englander, Jim Simons. The largest position is worth $11.1M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.